SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers (HIMS) is captivating investors following reports of a strategic partnership with Novo Nordisk to distribute GLP-1 weight-loss drugs, effectively resolving their prior legal dispute. This news has ignited a fervent community discussion predicting a significant short squeeze, given the stock's high short interest, though some analysts debate the long-term margin implications of the collaboration.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is generating significant bullish sentiment following the imminent departure of a key FDA official, which the community views as clearing the path for accelerated approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. High anticipation for a detailed Phase 3 data presentation and discussions of a substantial short squeeze are further fueling conversation.

iShares Trust - iShares Trust iShares Preferred and Income Securities ETF

iShares Preferred & Income Securities ETF

iShares Preferred & Income Securities ETF (PFF) is trending due to an unexpected and significant cut to its recent distribution, raising widespread community concern over the fund's predictability and a return of capital (ROC). Investors are actively debating whether this signals a fundamental management issue or a temporary reclassification, prompting many to consider alternative income-generating ETFs.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a massive surge amid community speculation that the impending departure of a key FDA official will pave the way for a more favorable regulatory path for its Huntington's disease gene therapy, igniting a sharp divide between bullish price targets and skeptical calls for caution given prior FDA setbacks for the program.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The Vanguard S&P 500 ETF ($VOO) is actively discussed as investors navigate market volatility driven by fluctuating inflation data, Federal Reserve policy speculation, and evolving geopolitical events. Despite mixed economic signals and a strong debate around an 'AI bubble,' many in the community view VOO as a reliable core holding for long-term wealth accumulation, citing significant recent inflows as a vote of confidence in broad market exposure.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending after reporting strong Q2 earnings and January sales, with notable growth in membership and digital commerce, leading to community discussion on its premium valuation amidst consistent performance and speculation about potential stock splits.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp. is a major talking point as NVIDIA commits a $2 billion investment to secure its optical networking and laser supply for next-gen AI infrastructure, signaling a critical industry shift towards light-based data transmission. This strategic funding, alongside its S&P 500 inclusion, highlights the company's pivotal role in addressing the 'photonics bottleneck' for AI data centers, driving strong investor sentiment and upward revisions from analysts.

Volatility Shares Trust - 1x Short VIX Futures ETF

Volatility Shares 1x Short VIX Futures ETF

SVIX is trending as the community actively buys this inverse volatility ETF, anticipating a 'VIX crush' and a return to lower market volatility following recent spikes. Traders are widely shorting VIX spikes with SVIX, believing its price will benefit as VIX futures eventually revert to lower, more stable levels amidst ongoing geopolitical and economic uncertainty.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSky Technology is trending due to recent multi-figure international defense contracts for its Gen-3 satellite intelligence solutions and fresh positive analyst coverage, positioning it firmly within the expanding space, defense, and AI sectors. The community sees significant long-term growth potential and undervaluation, though ongoing discussions around Gen-3 deployment and historical volatility remain key talking points.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is seeing significant discussion after mixed interim Phase 2 results for its cystic fibrosis therapy, ARCT-032, led to a sharp sell-off despite reported mucus reduction and safety. The community is actively debating if the market overreacted, pointing to the drug's progression to higher doses, an extended cash runway, and ongoing developments in its pipeline including a lawsuit against AbbVie and promising flu vaccine data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results, Beats Estimates By $0.06 EPS

Silence Therapeutics (NASDAQ:SLN - Get Free Report) released its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by...

Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?

The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six brokerages that are currently covering the company, MarketBeat Ratings...

Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1% - Here's What Happened

Silence Therapeutics (NASDAQ:SLN) Trading Down 5.1% - Time to Sell...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat...

Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% - Should You Sell?

Silence Therapeutics (NASDAQ:SLN) Shares Down 0.7% - Should You Sell...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the firm, MarketBeat Ratings...

Silence Therapeutics Announces Leadership Changes

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has...

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat...

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.14	--	--	N/A
Q4 '25	-$0.19	-$0.09	51.57%	BEAT
Q3 '25	-$0.19	-$0.15	19.81%	BEAT
Q2 '25	-$0.13	-$0.19	-43.41%	MISSED
Q1 '25	-$0.15	-$0.20	-31.04%	MISSED

SLN
Silence Therapeutics Plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SLN News

SLNSilence Therapeutics Plc - ADR